Acquired Hemophilia A Successfully Treated with Rituximab

Acquired hemophilia A (AHA) is a rare bleeding disorder due to the development of specific autoantibodies against factor VIII. The anti-CD20 monoclonal antibody Rituximab has been proven to be effective in obtaining a long-term suppression of inhibitors of AHA, besides other immunosuppressive standa...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Arena, Giovanni, Grandone, Elvira, Di Minno, Matteo Nicola Dario, Musto, Pellegrino, Di Minno, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344169/
https://www.ncbi.nlm.nih.gov/pubmed/25745551
http://dx.doi.org/10.4084/MJHID.2015.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344169/
https://www.ncbi.nlm.nih.gov/pubmed/25745551
http://dx.doi.org/10.4084/MJHID.2015.024

Ejemplares similares